Manibiotech, Here are the real lies:
1. DCVAX would never complete its trial. DCvax completed the trial with spectacular results.
2. Trial results will never be published in a reputable journal. TLD published by JAMA, discussed by NYAS, ASCO, SCO, etc
3. Production of 'personalized' dcvax would be too inefficient like dendreon/provenge. Automation, through Flaskwork, obtained.
4. NWBO would never be able to adequately protect DCVAX from BPs. NWBO's and ROSWELL's patents serve as a barrier of entry, preventing any BP from developing a competing dendritic-based treatment.
5. Wall-street would severely limit NWBO's ability to raise needed funding, resulting in preventing NWBO from crossing the finish line. NWBO not only got to the finish line, they may very well bankrupt money-makers and SHFs via the outcome of its lawsuit and open the floodgates for other companies to sue these bastards.
Despite all of this, you and others conclude NWBO management is incompetent. WHY?
Market Data 
Markets 
AI
